By Brandon Lowrey ( May 13, 2014, 7:30 PM EDT) -- The U.S. Food and Drug Administration on Monday urged a D.C. federal judge to dismiss Teva Pharmaceutical Industries Ltd.'s suit seeking to prevent the agency from approving generic versions of Teva's multiple sclerosis drug Copaxone without requiring additional clinical data, calling the suit "premature and ill-considered."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.